<DOC>
	<DOC>NCT01870908</DOC>
	<brief_summary>This study is to evaluate the safety and the effectiveness of treatment with tacrolimus and biological agents.</brief_summary>
	<brief_title>Special Drug Use-Results Survey of Prograf Capsule in Rheumatoid Arthritis Patients</brief_title>
	<detailed_description>The purpose of this study is to confirm the safety of 24 weeks-treatment with the combination of tacrolimus + biological agents, and to assess the efficacy using SDAI, CDAI, DAS28-CRP, MMP-3, MHAQ in patients with rheumatoid arthritis who have not achieved SDAI remission despite of using biological agents for over 8 weeks.</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>patients with rheumatoid arthritis who have been treated with biological agents over 8 weeks but have not achieved SDAI remission (SDAI &lt; 3.3)</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>